People with MS experience significant changes in cognition more than a year before significant physical decline is evident, a ...
At the Type B end-of-Phase 2 MS meeting with the U.S. Food and Drug Administration, FDA aligned with Clene acknowledging the limitations of the Expanded Disability Status Scale and expressed openness ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback